Strategic Wealth Partners Ltd. grew its holdings in Zoetis Inc. (NYSE:ZTS – Get Rating) by 37.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,113 shares of the company’s stock after purchasing an additional 4,631 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Zoetis were worth $3,227,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Norges Bank acquired a new stake in Zoetis in the fourth quarter valued at approximately $1,067,881,000. Arrowstreet Capital Limited Partnership raised its holdings in Zoetis by 171.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock valued at $627,335,000 after acquiring an additional 2,102,306 shares in the last quarter. Castleview Partners LLC acquired a new stake in Zoetis in the fourth quarter valued at approximately $6,000,000. BlackRock Inc. raised its holdings in Zoetis by 3.6% in the first quarter. BlackRock Inc. now owns 41,766,559 shares of the company’s stock valued at $7,876,755,000 after acquiring an additional 1,450,749 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in Zoetis by 24.4% in the first quarter. Wellington Management Group LLP now owns 6,301,310 shares of the company’s stock valued at $1,188,364,000 after acquiring an additional 1,234,738 shares in the last quarter. Hedge funds and other institutional investors own 91.05% of the company’s stock.
Wall Street Analyst Weigh In
ZTS has been the topic of several analyst reports. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. StockNews.com raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Friday, September 9th. Stifel Nicolaus cut their price objective on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, June 24th. The Goldman Sachs Group cut their price objective on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. Finally, Piper Sandler started coverage on shares of Zoetis in a report on Monday, July 11th. They set an “overweight” rating and a $205.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $224.00.
Insider Activity at Zoetis
Zoetis Stock Performance
Shares of ZTS opened at $160.99 on Wednesday. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. The firm has a market cap of $75.37 billion, a PE ratio of 36.51, a price-to-earnings-growth ratio of 2.87 and a beta of 0.77. The company’s 50 day simple moving average is $170.36 and its 200-day simple moving average is $175.28. Zoetis Inc. has a 12-month low of $154.18 and a 12-month high of $249.27.
Zoetis (NYSE:ZTS – Get Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the business posted $1.19 earnings per share. As a group, equities analysts predict that Zoetis Inc. will post 5.01 EPS for the current year.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.